Generation and Characterization of a Novel Anti-IL-17A Monoclonal Antibody for the Treatment of Psoriatic Arthritis
Interleukin-17A (IL-17A) plays a pivotal role in the pathogenesis of psoriatic arthritis. We generated a high-affinity monoclonal antibody against IL-17A using hybridoma technology and characterized its binding kinetics, neutralization potency, and in vivo efficacy in an experimental arthritis model. The antibody demonstrated superior affinity compared to existing therapeutics and significantly reduced disease severity in treated animals. These results support the potential of this novel antibody as a therapeutic candidate.
Authors
- Widad Abd Al-Jabbar Mozzan (ORCID: https://orcid.org/0000-0003-1944-5168)
- Hayder Al-Aubaidy (ORCID: https://orcid.org/0000-0001-9564-0120)
- Nada Khazal Kadhim Hindi (ORCID: https://orcid.org/0000-0001-5833-030X)
- Yasmeen Ali Hussien (ORCID: https://orcid.org/0000-0002-7898-0139)
- Ashwaq Al-jburi
Institutions
- Mustansiriyah University (IQ)
- University of Babylon (IQ)
- University of Alkafeel (IQ)
- Alsalam University College (IQ)
- Queensland Department of Education (AU)
Publication Details
- Journal
- Trends in Pharmaceutical Biotechnology
- Published
- 2025-06-30
- DOI
- https://doi.org/10.57238/tpb.2025.153196.1027
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80